Historic HIV Vaccine Trial Involving GeoVax Vaccine Spotlighted
in The Georgia Voice and The Body
Articles Highlight AIDS Research Consortium of Atlanta's Search for Volunteers
To Help Test Safety of GeoVax's Vaccine in 77-Week Trial
ATLANTA, GA, July 02, 2010 - GeoVax Labs, Inc. (OTCBB: GOVX), GOVX), a biotechnology
company dedicated to developing vaccines that prevent and fight human immunodeficiency virus
(HIV), is mentioned in two recent articles covering a historic HIV vaccine trial currently being
conducted by the AIDS Research Consortium of Atlanta (ARCA) using a vaccine supplied by GeoVax
The first article, titled "ARCA Seeks Volunteers For Historic HIV Vaccine Trial," appeared in
the June 11 print and online editions of The Georgia Voice, a publication focused on Georgia's
LGBT community. In the article, Voice reporter Matt Shafer notes that ARCA is currently
seeking volunteers to help test the safety of the GeoVax vaccine, which has shown the potential
of reversing HIV viral loads in HIV-positive individuals. He goes on to describe how the vaccine
works and details the stringent requirements for participation. The article quotes ARCA's
observation that this is the first therapeutic trial ever conducted using a promising HIV vaccine
candidate from GeoVax.
The second article, titled "Georgia: AIDS Research Consortium of Atlanta Seeks Volunteers for
Historic HIV Vaccine Trial," was posted on June 28 on the website The Body: The Complete
HIV/AIDS Resource. It is an excerpt of the Voice piece, once again reviewing ARCA's search
for trial subjects and stringent participation requirements.
GeoVax CEO Dr. Robert McNally commented, "As I pointed out to The Georgia Voice, we are
hopeful that this vaccine will reproduce its effects in humans the way it did in tests conducted on
primates. We anticipate that media coverage such as these articles will make it easier to recruit
appropriate test subjects, allowing us to initiate the trial in a timely fashion and accelerate our
quest to bring a viable vaccine to market."
To read The Georgia Voice’s article in its entirety, please visit:
To read The Body's article in its entirety, please visit:
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include developing AIDS
vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions
(FDA guidelines), conducting human trials for vaccine safety and effectiveness, and obtaining
regulatory approvals to move the product forward. All preventative phase 1 human clinical trials
conducted to date tested various combinations and doses of our DNA and MVA AIDS vaccines in
human volunteers for their demonstrated ability to raise anti-HIV immune responses as well as for their
safety. Successful results from all phase 1 testing supported the initiation of the first phase 2 testing.
GeoVax's phase 2 human trial began in January 2009 and will involve 225 participants at sites in the
United States and South America. Long term, we expect that GeoVax will grant manufacturing and
distribution rights in several global markets in return for upfront fees, collaborative development
agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and
distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.
Certain statements in this document are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in
these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use,
GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is
development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax
will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which
GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and
Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Robert McNally, President & CEO
(678) 384-7220 or email@example.com
Investor Relations Group:
James Carbonara / Jason Strominger
Janet Vasquez / Robin O’Malley
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.